Stereotactic body radiation therapy for medically inoperable early-stage lung cancer: Tata Memorial Hospital perspective and practice recommendations.

BACKGROUND: Stereotactic body radiotherapy (SBRT) is now considered the standard treatment for medically inoperable early-stage non-small lung cell cancer (ES-NSCLC). PURPOSE: There is a paucity of data related to outcomes with SBRT in ES-NSCLC from the developing countries. We report the early outcomes of ES-NSCLC patients treated with SBRT at our institute. MATERIALS AND METHODS: Between 2007 and 2015, 40 consecutive patients with histologically proven ES-NSCLC were treated with SBRT. Median age was 71 years (range: 46-88 years) and median Charlson comorbidity index (CCI) was 3. The majority had stage I (70%) and 45% of the tumors were centrally located. The median tumor diameter was 3.8 cm (range: 2-7.6 cm). The mean gross tumor volume was 41 cc (range: 4-139 cc) and the mean planning target volume (PTV) was 141 cc (range: 27-251 cc). Varying dose and fraction (fr) sizes were used depending on tumor location, tumor size, and treatment period. The median biologically effective dose (BED) was 77 Gy10 (range: 77-105 Gy10) for the initial cohort (2007-2012) and 105 Gy10 (range: 77-132 Gy10) for the subsequent cohort (2013-2015). RESULTS: After a median follow-up of 16 months (range: 3-99 months), the 2-year local control (LC), overall survival, and cancer-specific survival (CSS) rates were 94%, 41%, and 62%, respectively. The univariate and multivariate analysis determined CCI >3 and PTV >80.6 cc as significant predictors of worse OS and CSS (P< 0.01). The clinical stage, tumor location, BED, and treatment period (2007-2012 vs. 2013-2015) did not significantly predict any of the outcomes. The most common acute toxicities were skin erythema (10%), grade 1 esophagitis (8%), and exacerbation of previous chronic obstructive pulmonary disease (10%). Grade ≥2 late radiation pneumonitis was seen in 17.5%. One patient developed a rib fracture. No neurological or vascular complications were seen. CONCLUSIONS: SBRT results in excellent local control (LC) and acceptable survival in medically inoperable ES-NSCLC with minimal adverse effects. Charlson comorbidity index and target volume are important prognostic factors and may aid in patient selection.

Volume changes with stereotactic body radiation therapy in early lung cancer: Time trends and outcomes.

INTRODUCTION: Tumour response during stereotactic body radiotherapy (SBRT) could be heterogeneous and the pattern of response may be used as an early predictor for outcome. METHODS: Twenty-two consecutive patients with early lung cancer (ELC), treated with SBRT, were evaluated retrospectively for their gross tumour volume (GTV) changes during radiation therapy (RT). Kilo-voltage computed tomography scans (KVCTs) were acquired before every fraction and GTV was contoured manually on a total of 152 datasets. Tumour volume changes were noted with every fraction. The overall survival (OS), locoregional recurrence free survival (LRFS) and distant metastasis free survival (DMFS) were computed using the Kaplan-Meier method and comparisons were made using log-rank test. RESULTS: Of the 22 patients, six had T1 tumours and 16 had T2 tumours. Median GTV was 40.6 cc (range 7.3-140.2 cc) on CT1 (KVCT at first fraction) and 33.3 cc (range 4.1-83.4 cc) on CTlast (KVCT at last fraction), suggesting a 17.9% median volume reduction at RT completion. Increase in tumour volume was noted in 18 (81.8%) patients at some point during RT. In the mid-treatment scan, 12 (54.5%) patients had higher tumour volumes than in CT1, however, only six (27.3%) patient's GTV remained larger compared to the baseline at the end of treatment. The median follow-up was 12.4 months. The OS, LRFS and DMFS rate at 12 and 18 months were 86.4%, 88.2%, 62% and 64.8%, 75.6% and 37.2% respectively. Tumours that regressed in volume by >17.9% (median volume reduction at RT completion) had significantly worse OS and LRFS compared to those that regressed <17.9% (P = 0.03 and 0.01 respectively). CONCLUSION: Gross tumour volume undergoes significant changes during SBRT. Early regression in tumour volume may be used as a predictor of poor LRFS and OS.